Amalgamated Bank Increases Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Amalgamated Bank increased its position in REGENXBIO Inc. (NASDAQ:RGNX) by 9.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,613 shares of the biotechnology company’s stock after buying an additional 1,227 shares during the quarter. Amalgamated Bank’s holdings in REGENXBIO were worth $159,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGNX. WINTON GROUP Ltd raised its holdings in REGENXBIO by 79.9% in the second quarter. WINTON GROUP Ltd now owns 76,840 shares of the biotechnology company’s stock valued at $899,000 after buying an additional 34,136 shares during the period. American Century Companies Inc. increased its stake in shares of REGENXBIO by 16.8% in the second quarter. American Century Companies Inc. now owns 74,872 shares of the biotechnology company’s stock worth $876,000 after buying an additional 10,767 shares during the last quarter. Quest Partners LLC raised its holdings in REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock valued at $491,000 after acquiring an additional 41,645 shares in the last quarter. Acadian Asset Management LLC bought a new position in REGENXBIO during the 2nd quarter valued at $494,000. Finally, Arizona State Retirement System grew its holdings in REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 1,997 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Price Performance

REGENXBIO stock opened at $10.21 on Wednesday. The company has a market cap of $502.90 million, a P/E ratio of -1.74 and a beta of 1.22. REGENXBIO Inc. has a fifty-two week low of $9.93 and a fifty-two week high of $28.80. The firm’s 50 day simple moving average is $12.27 and its 200-day simple moving average is $14.45.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm had revenue of $22.30 million for the quarter, compared to analyst estimates of $22.97 million. During the same quarter in the prior year, the business earned ($1.66) EPS. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts expect that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $130,466.16. The sale was disclosed in a document filed with the SEC, which is available at this link. In other REGENXBIO news, Director Argeris N. Karabelas sold 11,000 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the transaction, the director now owns 11,286 shares of the company’s stock, valued at approximately $169,741.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total value of $115,600.00. Following the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $130,466.16. The disclosure for this sale can be found here. Insiders have sold 55,279 shares of company stock worth $762,934 over the last 90 days. 13.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on RGNX shares. Barclays lowered their price objective on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. The Goldman Sachs Group initiated coverage on REGENXBIO in a report on Friday, June 7th. They issued a “buy” rating and a $38.00 price target for the company. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research note on Wednesday, September 4th. Finally, StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.91.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.